These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23060591)

  • 81. Pemetrexed: translational research in breast cancer.
    Hanauske AR
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):40-2. PubMed ID: 12094337
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
    Arévalo E; Castañón E; López I; Salgado J; Collado V; Santisteban M; Rodríguez-Ruiz M; Martín P; Zubiri L; Patiño-García A; Rolfo C; Gil-Bazo I
    J Transl Med; 2014 Apr; 12():98. PubMed ID: 24726028
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
    Adjei AA
    Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Plasma thymidylate synthase and dihydrofolate reductase mRNA levels as potential predictive biomarkers of pemetrexed sensitivity in patients with advanced non-small cell lung cancer.
    Li T; Huang JB; Lu JG; Li R; Wang Y; Shi XR; Shi MX; Zhang XD
    J Thorac Dis; 2020 Dec; 12(12):7313-7319. PubMed ID: 33447420
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
    Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
    Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
    Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Fiala O; Pesek M; Skrickova J; Kolek V; Salajka F; Tomiskova M; Satankova M; Kultan J; Kuliskova J; Svaton M; Hrnciarik M; Hejduk K; Chloupkova R; Topolcan O; Hornychova H; Nova M; Ryska A; Finek J
    Tumour Biol; 2017 Feb; 39(2):1010428317691186. PubMed ID: 28218046
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
    Wang X; Wang Y; Wang Y; Cheng J; Wang Y; Ha M
    J Biomed Sci; 2013 Jan; 20(1):5. PubMed ID: 23350714
    [TBL] [Abstract][Full Text] [Related]  

  • 90. CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.
    Grabauskiene S; Bergeron EJ; Chen G; Chang AC; Lin J; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
    Lung Cancer; 2013 Dec; 82(3):477-84. PubMed ID: 24113549
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
    Hanauske AR; Chen V; Paoletti P; Niyikiza C
    Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555
    [TBL] [Abstract][Full Text] [Related]  

  • 92. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
    Hashemi Sadraei N; Feng Y; Du L; Fu P; Haque S; Dowlati A; Gollamudi J; Pennell NA; Mekhail T; Avril S; Farver C; Gerson SL; Sharma N
    Lung Cancer; 2018 Dec; 126():48-54. PubMed ID: 30527192
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Pemetrexed in the treatment of selected solid tumors.
    Adjei AA
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):50-3. PubMed ID: 12023793
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Thymidylate synthase inhibitors for non-small cell lung cancer.
    Galvani E; Peters GJ; Giovannetti E
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1343-56. PubMed ID: 21905922
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
    Adjei AA
    Lung Cancer; 2001 Dec; 34 Suppl 4():S103-5. PubMed ID: 11742712
    [TBL] [Abstract][Full Text] [Related]  

  • 96. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
    Sowers R; Toguchida J; Qin J; Meyers PA; Healey JH; Huvos A; Banerjee D; Bertino JR; Gorlick R
    Mol Cancer Ther; 2003 Jun; 2(6):535-41. PubMed ID: 12813132
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma.
    Lee SW; Chen TJ; Lin LC; Li CF; Chen LT; Hsing CH; Hsu HP; Tsai CJ; Huang HY; Shiue YL
    Exp Mol Pathol; 2013 Aug; 95(1):83-90. PubMed ID: 23726796
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Tetrahydrohomofolate polyglutamates as inhibitors of thymidylate synthase and glycinamide ribonucleotide formyltransferase in Lactobacillus casei.
    Thorndike J; Kisliuk RL; Gaumont Y; Piper JR; Nair MG
    Arch Biochem Biophys; 1990 Mar; 277(2):334-41. PubMed ID: 2106831
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical Experience With Pemetrexed in Breast Cancer.
    Martin M
    Semin Oncol; 2006 Feb; 33(Suppl 2):S15-8. PubMed ID: 16472713
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
    Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.